# Pyxis Oncology

Source: https://onco.cc/companies/pyxis-oncology/  
OnCo record `pyxis-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A listed Boston company developing an antibody-drug conjugate, a drug that carries a toxin into the tumour, aimed at a protein found in the tissue around cancers. It is in early trials, mainly for head and neck cancer that has come back or spread.

## Summary

Pyxis Oncology develops antibody-drug conjugates and immunotherapy antibodies. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an ADC with an auristatin payload that targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tumour's extracellular matrix rather than a protein on the cancer cell. It is in Phase 1 as a single agent (NCT05720117) and with pembrolizumab (NCT06795412, Phase 1/2, with Merck Sharp & Dohme as collaborator), with a focus on recurrent or metastatic head and neck squamous cell carcinoma. The company says the FDA granted Fast Track designation for R/M HNSCC that has progressed after platinum chemotherapy and an anti-PD-(L)1 therapy. Pyxis trades on Nasdaq under PYXS according to its SEC filings.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Pyxis Oncology, Inc.; Pyxis Oncology, Inc
- HQ: Boston, MA
- Type: biotech
- Website: https://pyxisoncology.com/
- Ticker: NASDAQ: PYXS

## Notes

- Founding year not stated on the pages read.
- The FN1 target link is for EDB+FN, a splice variant of fibronectin 1.
- NCT05720117 was confirmed through the ClinicalTrials.gov v2 API but is not yet a trial record in OnCo.

## Sources

- Official website: https://pyxisoncology.com/
- Clinical programs and pipeline: https://pyxisoncology.com/clinical-programs/
- ClinicalTrials.gov NCT05720117: https://clinicaltrials.gov/study/NCT05720117
- ClinicalTrials.gov NCT06795412: https://clinicaltrials.gov/study/NCT06795412
- SEC EDGAR filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001782223
- RA Capital portfolio entry: https://www.racap.com/portfolio/pyxis-oncology

## Connected records

- cancers: [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [FN1](https://onco.cc/targets/fn1/)
- drugs: [Micvotabart pelidotin](https://onco.cc/drugs/micvotabart-pelidotin/)
- trials: [A Study of PYX-201 in Advanced Solid Tumors](https://onco.cc/trials/nct05720117/), [Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors](https://onco.cc/trials/nct06795412/)
- companies: [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/pyxis-oncology.json